#USA #PBI-Gordon #TriviumVet #Felycin #Shawnee

PBI-Gordon Companies Expands Pet Health Solutions with TriviumVet Acquisition

PBI-Gordon Companies, Inc., known for driving innovation in pet health and green spaces, has announced a significant milestone in its business strategy. The latest move involves acquiring TriviumVet®, a pioneering research and development firm focused on creating advanced treatments for chronic health conditions in dogs and cats. This acquisition represents not only the largest transaction in the company's remarkable 77-year history but also the addition of an exciting product, Felycin®-CA1, to the PRN® Pharmacal portfolio.

On May 5, 2025, the announcement shed light on a collaboration aimed at delivering innovative solutions to improve the quality of life for pets. Louise Grubb, Co-Founder of TriviumVet, emphasized the shared belief that pets deserve advanced care similar to that provided to humans. The partnership between PBI-Gordon and TriviumVet is focused on bringing cutting-edge treatments to pet owners globally, ensuring that both pets and their caregivers have access to the best healthcare options.

Product Spotlight: Felycin®-CA1

A notable product from this acquisition is Felycin®-CA1, the first drug conditionally approved by the U.S. Food and Drug Administration (FDA) to manage ventricular hypertrophy in cats suffering from subclinical hypertrophic cardiomyopathy (HCM), a condition that affects an estimated one in seven felines. Dr. Stuart Fitzgerald, a veterinary expert, noted the importance of treatment access and awareness, stating that better management strategies can lead to increased longevity and health quality for these cats.

Veterinary practices will be able to order Felycin®-CA1 starting this August, while PBI-Gordon plans to expand its workforce by hiring over 50 new employees. This strategic move aims not only to promote the new product but also to engage pet owners in the conversation around pet healthcare, and to ensure a successful launch into the market.

Addressing Unmet Needs in Pet Health

The integration of TriviumVet’s innovative pipeline into PBI-Gordon’s existing frameworks comes with the promise of addressing crucial health issues facing pets today. The company is focused on developing solutions for conditions such as feline chronic kidney disease, pain management in canines, and gastric ulcers. The treatments are designed to empower pet owners, enabling them to actively enhance their pets’ quality of life and improve overall healthcare outcomes.

Stephen Clifford, President and CEO of PBI-Gordon Companies, emphasized that this acquisition not only marks a significant advancement in the treatment of feline HCM but also enhances the company’s ability to grow its companion animal health pharmaceutical business. He pointed out that the merger reflects a shared philosophy in development, promoting innovation and identifying unmet needs through collaboration across scientific, regulatory, and commercial domains.

Continued Commitment to Pet Health

As part of the acquisition, Louise Grubb will continue to lead TriviumVet as Managing Director, effectively transforming it into a subsidiary under the PBI-Gordon umbrella while still operating independently in Waterford, Ireland. The strategic alignment will ensure that the research and development team collaborates closely with PBI-Gordon to enhance the innovative product line further.

This acquisition demonstrates PBI-Gordon's steadfast commitment to the future of pet health by investing in groundbreaking treatments and emphasizing the importance of veterinary care. The company's long-standing tradition of supporting the health and wellbeing of animals signifies a promising future for pet owners looking for reliable, advanced healthcare solutions for their beloved companions.

In conclusion, the acquisition of TriviumVet marks a transformative step in the evolution of pet healthcare with a focus on addressing critical health issues in cats and dogs. As the two organizations combine efforts, they strengthen their mission to elevate the standards of care that pets receive, continuing to break new ground in veterinary innovation.